Compare · MRNA vs TCRX
MRNA vs TCRX
Side-by-side comparison of Moderna Inc. (MRNA) and TScan Therapeutics Inc. (TCRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TCRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.53B, about 410.3x TCRX ($59.8M).
- Over the past year, MRNA is up 97.7% and TCRX is down 49.9% - MRNA leads by 147.6 points.
- MRNA has been more active in the news (11 items in the past 4 weeks vs 3 for TCRX).
- MRNA has more recent analyst coverage (25 ratings vs 9 for TCRX).
- Company
- Moderna Inc.
- TScan Therapeutics Inc.
- Price
- $61.80-2.14%
- $0.91+1.44%
- Market cap
- $24.53B
- $59.8M
- 1M return
- +11.57%
- +5.58%
- 1Y return
- +97.70%
- -49.91%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 11
- 3
- Recent ratings
- 25
- 9
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
TScan Therapeutics Inc.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester
Latest TCRX
- TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- TScan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
- Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
- SEC Form 4 filed by Director Baker Bros. Advisors Lp
- SEC Form 4 filed by Director Nicholson Garry A
- SEC Form 4 filed by Director Woods Keith
- TScan Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Gruia Gabriela
- SEC Form 4 filed by Director Dorton Katina